BioNetwork 2017

October 23 - 25, 2017

The Ritz-Carlton, Laguna Niguel, CA


Sponsors & Exhibitors


Back Bay Life Science Advisors


Back Bay Life Science Advisors (Back Bay or BBLSA) is a Life Science Sector strategic consulting and financial advisory firm. The senior leadership has extensive and broad reaching aggregate strategic and transactional experience, serving both large and emerging company needs for significant and sustainable growth. 
Central to Back Bay’s value proposition is a holistic approach to meeting clients’ needs via multi-disciplinary and cross functional project management and deal execution.   We believe deeply that commercial assessment in the absence of expert scientific and clinical understanding misses key detail related to adoptive drivers and strategic growth challenges.  

Similarly, extensive scientific or clinical acumen absent disciplined commercial analytics, experience and insights overlooks highly relevant data and can lead conclusions astray. Lastly, transactional decisions and considerations, whether internal investment or external acquisition, divestiture or sale, demands a rigorous analysis of inflection points and sensible valuation metrics; itself driven by the combination of technical and commercial acumen, as described above.
Back Bay’s model emphasizes leadership team presence, oversight and execution in all aspects of an assignment, leveraging the range of our collective insight and experiences.  Finding the right answer and then getting it done is where Back Bay excels. 

Please visit – for more information or watch the Back Bay video. 

Capital One Healthcare


Capital One® Healthcare is a leading provider of financial services to the industry. Customers across healthcare sectors—including senior housing, healthcare services, pharmaceuticals, medical devices, healthcare IT and medical offices—rely on Capital One Healthcare to finance acquisitions, refinance existing debt, support working capital needs and fund growth initiatives. With in-depth expertise, our team of professionals creates solutions tailored to meet the needs of our customers. Capital One Healthcare is a part of Capital One Commercial Banking, which leverages a relationship-based banking model that seamlessly delivers an array of products and services including loans and deposit accounts, treasury management services, merchant services, investment banking, international services and correspondent banking.

DRI Capital


DRI Capital is a pioneer and global leader in healthcare investing and was the original innovator of the healthcare royalty market. The firm, originally called Drug Royalty Corporation, was founded in 1992 to purchase royalty streams on pharmaceutical products and to make healthcare equity investments. In 1993, the firm was listed on the Toronto Stock Exchange and remained publicly traded until 2002 when it was purchased by its current owners and taken private. In 2006, DRI Capital successfully raised $800 million ($240 million in equity and $560 million in debt) for its first managed fund, Drug Royalty I. With Drug Royalty I, DRI completed its transition to a private equity fund manager business model. In 2010, DRI successfully raised $926 million of capital commitments ($701 million in equity for its second managed fund, Drug Royalty II, and $225 million in equity for Drug Royalty II Co-Investment Fund). On September 9, 2013, DRI announced the final closing of its third managed fund, Drug Royalty III, with US $1.45 billion of equity commitments from a global pool of institutional investors. 

As of June 30, 2014, Drug Royalty I, Drug Royalty II and Drug Royalty III have collectively acquired over 50 separate royalty streams from inventors, universities, research institutes, hospitals, biotechnology and global pharmaceutical companies payable on 30 different leading pharmaceutical products. In building this portfolio, DRI led the way with numerous milestone transactions, including the first transaction outside the United States, the first transaction with an individual inventor, the first transaction on a diagnostic, the first transaction on a life science tool and the first transaction involving a bundle of royalty streams. Further, DRI's managed funds have completed more repeat transactions with prior counterparties than any other royalty monetization firms, reinforcing DRI's leading reputation in the industry.

Today DRI Capital is a fully-integrated team of more than 30 investment professionals and support staff with well over U.S. $3 billion under management, focused on identifying, assessing, acquiring and managing biopharmaceutical royalty assets across the globe. Collectively, the professional team has over 150 years of experience. The team has individuals with backgrounds in the pharmaceutical industry, as well as in scientific, financial, healthcare, intellectual property and legal disciplines. This breadth of knowledge and training allows DRI Capital to identify unique potential investments and conduct its due diligence on such investments quickly and effectively.

Foley Hoag


Foley Hoag is a dynamic law firm that represents public and private clients in a wide range of disputes and transactions worldwide. We have expertise in industries such as life sciences and healthcare, technology and professional services. Our life sciences practice understands the competitive,regulatory and litigation challenges that arise when developing and introducing new products and technologies to the global marketplace, and our lawyers are ready to help clients overcome these obstacles. From initial conception to commercial viability, from market success to expansion, we provide our clients with strategic and practical legal advice that is tailored to each of our clients' unique goals. Our team of former scientists, engineers, researchers,physicians, and political advisors are focused on helping clients succeed through the delivery of exceptional legal service. For more information, visit



Morrison & Foerster


From concept to commercialization and through exit, Morrison & Foerster’s Life Sciences Group represents more than 600 life sciences, health care companies, research institutions and the venture capital funds and investment banks that finance them, helping our clients protect their valuable assets and bring their ideas to market. Our corporate, transactional, intellectual property, and litigation attorneys share the value our clients place on the combination of scientific and business success. With more than 180 life sciences lawyers around the world, and more than 60 PhDs in relevant scientific disciplines, our fully integrated team has the depth of practice and global reach that are critical in today’s global life sciences market. Our knowledge and superior experience in pharmaceuticals, biologics, diagnostics, medical devices, vaccines, and over-the-counter products means that we understand the complex technologies at the heart of our clients’ businesses.



Viscadia supports our Business Development & Licensing clients by helping executives identify and thoroughly evaluate acquisition/licensing
targets in alignment with portfolio and corporate strategy.  We execute a disciplined decision support process, the cornerstone of which is the comprehensive and dynamic Viscadia ACE™ forecast model, supported by detailed primary and secondary market research, data room assessment and market landscape analysis.  The findings and projections resulting from our process are distilled into a professional presentation suitable for executive audiences.